About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer

Molecular and Cellular Endocrinology

Volumn 219, Issue 1-2, 2004, Pages 1-7

  Lacroix, M ^a   Leclercq, G ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; GATA 3; HNF 3 ; Oestrogen receptor ; TFF1; XBP 1

Indexed keywords

BINDING PROTEIN; ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

BINDING SITE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA BINDING; GATA3 GENE; GENE; GENE EXPRESSION; HNF3A GENE; HUMAN; PRIORITY JOURNAL; REVIEW; XBP 1 GENE;

EID: 2442670465     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2004.02.021     Document Type: Review

References (67)

1. Al-Azzeh E.D., Fegert P., Blin N., Gott P. Transcription factor GATA-6 activates expression of gastroprotective trefoil genes TFF1 and TFF2. Biochim. Biophys. Acta. 1490:2000;324-332
2. Barkhem T., Haldosen L.A., Gustafsson J.A., Nilsson S. Transcriptional synergism on the pS2 gene promoter between a p160 coactivator and estrogen receptor-alpha depends on the coactivator subtype, the type of estrogen response element, and the promoter context. Mol. Endocrinol. 16:2002;2571-2581
3. Beck S., Sommer P., dos Santos Silva E., Blin N., Gott P. Hepatocyte nuclear factor 3 (winged helix domain) activates trefoil factor gene TFF1 through a binding motif adjacent to the TATAA box. DNA Cell. Biol. 18:1999;157-164
4. Bertucci F., Houlgatte R., Benziane A., Granjeaud S., Adelaide J., Tagett R., Loriod B., Jacquemier J., Viens P., Jordan B., Birnbaum D., Nguyen C. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum. Mol. Genet. 9:2000;2981-2991
5. Bossenmeyer-Pourié C., Kannan R., Ribieras S., Wendling C., Stoll I., Thim L., Tomasetto C., Rio M.C. The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell. Biol. 157:2002;761-770
6. Bouras T., Southey M.C., Chang A.C., Reddel R.R., Willhite D., Glynne R., Henderson M.A., Armes J.E., Venter D.J. Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res. 62:2002;1289-1295
7. Cereghini S. Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 10:1996;267-282
8. Chen C.H., Zhang D.H., LaPorte J.M., Ray A. Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J. Immunol. 165:2000;5597-5605
9. Cirillo L.A., McPherson C.E., Bossard P., Stevens K., Cherian S., Shim E.Y., Clark K.L., Burley S.k., Zaret K.S. Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J. 17:1998;244-254
10. Clark K.L., Halay E.D., Lai E., Burley S.K. Co-crystal structure of the HNF-3/fork head DNA-recognition motif resembles histone H5. Nature. 364:1993;412-420
11. Costa R.H., Grayson D.R., Darnell J.E. Jr. Multiple hepatocyte-enriched nuclear factors function in the regulation of transthyretin and alpha 1-antitrypsin genes. Mol. Cell. Biol. 9:1989;1415-1425
12. Cunliffe H.E., Ringner M., Bilke S., Walker R.L., Cheung J.M., Chen Y., Meltzer P.S. The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res. 63:2003;7158-7166
13. Dignass A., Lynch-Devaney K., Kindon H., Thim l., Podolsky D.K. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J. Clin. Invest. 94:1994;376-383
14. Ding L., Yan J., Zhu J., Zhong H., Lu Q., Wang Z., Huang C., Ye Q. Ligand-independent activation of estrogen receptor alpha by XBP-1a. Nucleic Acids Res. 31:2003;5266-5274
15. Dou Q.P., Smith D.M., Daniel K.G., Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog. Cell. Cycle Res. 5:2003;441-446
16. Flouriot G., Griffin C., Kenealy M., Sonntag-Buck V., Gannon F. Differentially expressed messenger RNA isoforms of the human estrogen receptor-alpha gene are generated by alternative splicing and promoter usage. Mol. Endocrinol. 12:1998;1939-1954
17. Gao N., Zhang J., Rao M.A., Case T.C., Mirosevich J., Wang Y., Jin R., Gupta A., Rennie P.S., Matusik R.J. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 17:2003;1484-1507
18. Gibson G.G., el-Sankary W., Plant N.J. Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 181-182:2002;199-202
19. Gillesby B.E., Zacharewski T.R. pS2 (TFF1) levels in human breast cancer tumor samples: correlation with clinical and histological prognostic markers. Breast Cancer Res. Treat. 56:1999;253-265
20. Gruvberger S., Ringner M., Chen Y., Panavally S., Saal L.H., Borg A., Ferno M., Peterson C., Meltzer P.S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61:2001;5979-5984
21. Hoch R.V., Thompson D.A., Baker R.J., Weigel R.J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int. J. Cancer. 84:1999;122-128
22. Jacob A., Budhiraja S., Reichel R.R. The HNF-3alpha transcription factor is a primary target for retinoic acid action. Exp. Cell. Res. 250:1999;1-9
23. Kaestner K.H. The hepatocyte nuclear factor 3 (HNF3 or FOXA) family in metabolism. Trends Endocrinol. Metab. 11:2000;281-285
24. Kaufman R.J. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 110:2002;1389-1398
25. Kim J., Petz L.N., Ziegler Y.S., Wood J.R., Potthoff S.J., Nardulli A.M. Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells. J. Steroid Biochem. Mol. Biol. 74:2000;157-168
26. Klein-Hessling S., Jha M.K., Santner-Nanan B., Berberich-Siebelt F., Baumruker T., Schimpl A., Serfling E. Protein kinase A regulates GATA-3-dependent activation of IL-5 gene expression in Th2 cells. J. Immunol. 170:2003;2956-2961
27. Kopachik W., Hayward S.W., Cunha G.R. Expression of hepatocyte nuclear factor-3alpha in rat prostate, seminal vesicle, and bladder. Dev. Dyn. 211:1998;131-140
28. Kristensen V.N., Borresen-Dale A.L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat. Res. 462:2000;323-333
29. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res. Treat. 83:2004;249-289
30. Leclercq, G., Lacroix, M., Seo, H.S., Larsimont, D., 2002. Mechanisms regulating oestrogen receptor alpha expression in breast cancer. In: Krstic-Demonacos, M., Demonacos, C. (Eds.), Molecular Mechanisms of Action of Steroid Hormone Receptors. Research Signpost, Trivandrum, Kerala, India, pp. 65-75.
31. Lee A.H., Iwakoshi N.N., Anderson K.C., Glimcher L.H. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. U.S.A. 100:2003;9946-9951
32. Lefebvre O., Chenard M.P., Masson R., Linares J., Dierich A., LeMeur M., Wendling C., Tomasetto C., Chambon P., Rio M.C. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 274:1996;259-262
33. Lu D., Kiriyama Y., Lee K.Y., Giguere V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Res. 61:2001;6755-6761
34. Luqmani Y.A., Ryall G., Shousha S., Coombes R.C. An immunohistochemical survey of pS2 expression in human epithelial cancers. Int. J. Cancer. 50:1992;302-304
35. McPherson C.E., Shim E.Y., Friedman D.S., Zaret K.S. An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array. Cell. 75:1993;387-398
36. Métivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell. 115:2003;751-763
37. Nunez A.M., Berry M., Imler J.L., Chambon P. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J. 8:1989;823-829
38. Osborne C.K., Schiff R., Fuqua S.A., Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin. Cancer Res. 7:2001;4338s-4342s
39. Perez-Stable C.M., Pozas A., Roos B.A. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol. Cell. Endocrinol. 167:2000;43-53
40. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature. 406:2000;747-752
41. Piao Y.S., Peltoketo H., Vihko P., Vihko R. The proximal promoter region of the gene encoding human 17beta-hydroxysteroid dehydrogenase type 1 contains GATA, AP-2, and Sp1 response elements: analysis of promoter function in choriocarcinoma cells. Endocrinology. 138:1997;3417-3425
42. Playford R.J., Marchbank T., Chinery R., Evison R., Pignatelli M., Boulton R.A., Thim L., Hanby A.M. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology. 108:1995;108-116
43. Poulsom R., Hanby A.M., Lalani E.N., Hauser F., Hoffmann W., Stamp G.W. Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J. Pathol. 183:1997;30-38
44. Rider V., Abdou N.I. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int. Immunopharmacol. 1:2001;1009-1024
45. Robyr D., Gegonne A., Wolffe A.P., Wahli W. Determinants of vitellogenin B1 promoter architecture. HNF3 and estrogen responsive transcription within chromatin. J. Biol. Chem. 275:2000;28291-28300
46. Ross D.T., Perou C.M. A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. Dis. Markers. 17:2001;99-109
47. Rutkowski D.T., Kaufman R.J. A trip to the ER: coping with stress. Trends Cell. Biol. 14:2004;20-28
48. Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H., Tu I.P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J., Kristensen G.B., Borresen-Dale A.L., Hastie T., Tibshirani R., van de Rijn M., Teng N.N., Longacre T.A., Botstein D., Brown P.O., Sikic B.I. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell. 14:2003;4376-4386
49. Sewack G.F., Hansen U. Nucleosome positioning and transcription- associated chromatin alterations on the human estrogen-responsive pS2 promoter. J. Biol. Chem. 272:1997;31118-31129
50. Shim E.Y., Woodcock C., Zaret K.S. Nucleosome positioning by the winged helix transcription factor HNF3. Genes Dev. 12:1998;5-10
51. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98:2001;10869-10874
52. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., Deng S., Johnsen H., Pesich R., Geisler S., Demeter J., Perou C.M., Lonning P.E., Brown P.O., Borresen-Dale A.L., Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100:2003;8418-8423
53. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., Martiat P., Fox S.B., Harris A.L., Liu E.T. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 100:2003;10393-10398
54. Stephensen C.B., Rasooly R., Jiang X., Ceddia M.A., Weaver C.T., Chandraratna R.A., Bucy R.P. Vitamin A enhances in vitro Th2 development via retinoid X receptor pathway. J. Immunol. 168:2002;4495-4503
55. Suzuki T., Moriya T., Sugawara A., Ariga N., Takabayashi H., Sasano H. Retinoid receptors in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Res. Treat. 65:2001;31-40
56. Takemoto N., Arai K., Miyatake S. Cutting edge: the differential involvement of the N-finger of GATA-3 in chromatin remodeling and transactivation during Th2 development. J. Immunol. 169:2002;4103-4107
57. Taylor K.M., Morgan H.E., Johnson A., Hadley L.J., Nicholson R.I. Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters. Biochem. J. 375:2003;51-59
58. Tomaru Y., Kondo S., Suzuki M., Hayashizaki Y. A comprehensive search for HNF-3alpha-regulated genes in mouse hepatoma cells by 60 K cDNA microarray and chromatin immunoprecipitation/PCR analysis. Biochem. Biophys. Res. Commun. 310:2003;667-674
59. Tomasetto C., Masson R., Linares J.L., Wendling C., Lefebvre O., Chenard M.P., Rio M.C. pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterology. 118:2000;70-80
60. Torres L.F., Karam S.M., Wendling C., Chenard M.P., Kershenobich D., Tomasetto C., Rio M.C. Trefoil factor 1 (TFF1/pS2) deficiency activates the unfolded protein response. Mol. Med. 8:2002;273-282
61. Vallet V., Antoine B., Chafey P., Vandewalle A., Kahn A. Overproduction of a truncated hepatocyte nuclear factor 3 protein inhibits expression of liver-specific genes in hepatoma cells. Mol. Cell. Biol. 15:1995;5453-5460
62. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536
63. Wang D.Y., Fulthorpe R., Liss S.N., Edwards E.A. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol. Endocrinol. 18:2004;402-411
64. West M., Blanchette C., Dressman H., Huang E., Ishida S., Spang R., Zuzan H., Olson J.A. Jr., Marks J.R., Nevins J.R. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11462-11467
65. Wright N.A. Trefoil peptides and the gut. Gut. 34:1993;577-579
66. Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 107:2001;881-891
67. Yu D.C., Sakamoto G.T., Henderson D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59:1999;1498-1504